Sunday, November 22, 2026

Explained — Why Dr. Reddy’s Laboratories shares are down in a strong market

Date:

Shares of Dr Reddy’s Laboratories Ltd. declined nearly 3% on Wednesday, April 15, after the recent developments on its weight-loss drug applications in Brazil and Canada and brokerage firm Citi’s subsequent negative outlook on the stock.Brazil’s regulator has denied the registration of semaglutide as the filing did not meet all technical requirements. The Brazil market has around 16 applications for semaglutide.

Apotex has gotten a tentative nod from the US Food and Drug Administration (USFDA) for semaglutide. Meanwhile, Dr Reddy’s is awaiting the final approval for semaglutide in Canada.

Meanwhile, brokerage firm Citi has a ‘sell’ rating on the stock with a price target of ₹1,070 per share.The brokerage said the rejection prevents the company from participating in the initial wave of semaglutide in Brazil. Dr. Reddy’s has missed the early opportunity in a competitive market with 16 pending applications in Brazil, Citi’s note said.

Apotex’s tentative nod in the US suggest that it may gain a lead over Dr Reddy’s in Canada, the brokerage added.

Shares of Dr. Reddy’s Laboratories are looking to recover from the lows of the day, currently trading 1.8% lower at ₹1,213. The stock is down 5% in the last one month and as a result, has turned negative for the year.

Also Read: Wipro shares rise after $71 million deal; eyes growth in AI services

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

CLSA sees better US-India trade outlook; expects Fed and RBI to raise rates in December

The US is likely to push ahead with trade...

‘Trump has cost us’: After midterm losses, MAGA asks if it’s over

As Republicans faced a nationwide drubbing in Tuesday’s midterm...

Prashant Jain sees 12-15% annual returns from Indian equities over 3-5 years

Question We've had a very painful period for the equity...

Raamdeo Agrawal sees FIIs return as earnings improve and valuations turn attractive

Question Looking at the valuation compression across the market, are...